Doctors used words such as "inoperable" and "incurable," effectively telling me that this cancer would kill me sooner or later.

Compared to people without liver steatosis, those with the condition had greater noncalcified coronary plaque burden and ...

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts ...

Collecting BMI data could further research into why women with lung cancer have better survival outcomes than men.An ...

Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper ...

Researchers at Mass General Brigham Heart and Vascular Institute found that people with hepatic steatosis, commonly called ...

Scientists at The Hormel Institute say they have made new discoveries about a protein that could play a key role in how liver ...

A pioneering Chinese study has found that a new drug cocktail administered before surgery, can nearly double the time patients with a deadly form of liver cancer live without the disease returning.

A new study suggests that Resmetirom may do more than treat fatty liver disease — it could also help stop liver cancer from ...

The University of Alabama at Birmingham Division of Transplantation now offers liver transplantation for patients with ...

In clinical trials, the drug was shown to almost double the median survival time for patients with pancreatic cancer.